BioCryst Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
The company is maintaining strong revenue growth for ORLADEYO, with robust new patient demand and a stable payer mix. Navenibart's phase III enrollment will complete soon, with a BLA filing planned for late 2027, and the Netherton syndrome program expects key data by year-end.
-
Management outlined a strategy to build a diversified rare disease portfolio by 2030, leveraging ORLADEYO's growth and recent business development moves. Navenibart's pivotal data and BLA filing are expected by end of next year, while the Netherton syndrome program aims for proof-of-concept results by year-end.
-
Q1 2026 saw 17% revenue growth and a 25% rise in non-GAAP operating profit, driven by strong ORLADEYO performance and successful Astria integration. Guidance for 2026 is unchanged, with robust liquidity and continued pipeline progress, despite a minor pediatric manufacturing delay.
-
Revenue growth is driven by strong U.S. performance, expanding prescriber base, and high patient retention among super-responders. The pipeline is advancing with navenibart and a KLK5 inhibitor, while pediatric and community market penetration continues to rise.
-
Record ORLADEYO growth, European divestiture, and the Astria acquisition marked a transformative year, with profitability achieved and a strong cash position. ORLADEYO is on track for $1B peak sales by 2029, while pipeline assets like navenibart and BCX17725 drive future growth.
Fiscal Year 2025
-
Delivered record 2025 revenue and profitability, driven by ORLADEYO growth and strategic portfolio expansion. 2026 guidance projects continued double-digit revenue growth, with new pediatric and injectable HAE therapies advancing and strong U.S. market focus.
-
Management outlined strong ORLADEYO growth, with $1B peak sales targeted by 2029, and detailed the strategic rationale and expected synergies from the Astria acquisition. Nevenabart is positioned for a late-2028 launch, while pipeline updates and disciplined expense management support ongoing profitability.
-
Orladeyo delivered 37% year-over-year revenue growth and maintained high patient retention despite new competition. The company improved its financial position by selling its European business, repaying debt, and raising guidance, while advancing its pipeline and preparing for the Astria acquisition.
-
The acquisition brings a late-stage HAE therapy, Nevenibart, into the portfolio, supporting a rare disease growth strategy and leveraging existing commercial infrastructure. The deal is expected to be accretive, with minimal incremental costs, and positions the company for double-digit revenue growth through 2033.
-
ORLADEYO is on track for $580–$600 million in global sales this year, with strong growth and patent protection through 2039. The company is selling its European business to focus on the U.S. and is actively seeking late-stage rare disease assets, while advancing its pipeline in Netherton syndrome and DME.
-
Record Q2 revenue and patient demand for ORLADEYO drove 45% year-over-year growth, with strong U.S. performance and expanding prescriber base. Sale of the European business will enable full debt repayment and further strengthen financials, supporting future pipeline and acquisition opportunities.
-
The sale of the European business for $250 million upfront and up to $14 million in milestones will enable debt repayment, $50 million in annual cost savings, and a focus on high-margin U.S. operations. The deal strengthens financials, accelerates pipeline development, and positions the company for future growth.
-
Strong commercial momentum and payer adoption for ORLADEYO are driving profitability ahead of schedule, with a robust pipeline targeting rare diseases and eye disorders. Financial discipline supports both debt reduction and future growth, positioning the company for significant market expansion.
-
ORLADEYO continues strong commercial growth, with raised revenue guidance and profitability expected this year. Two clinical programs—17725 for Netherton syndrome and Avoralstat for DME—are progressing, with key data updates anticipated by year-end.
-
Strong Q1 growth and high paid rates position ORLADEYO for robust U.S. and global sales targets. Pipeline advances in Netherton syndrome and DME offer potential for sustainable growth, with key clinical data expected by year-end.
-
Profitability and strong cash generation are driven by ORLADEYO's commercial success and expanding reimbursement. The pipeline includes late-stage programs for Netherton syndrome and diabetic macular edema, with key data readouts and regulatory milestones expected by year-end.
-
Q1 2025 saw record ORLADEYO revenue, a rapid rise in paid patient rates, and raised annual guidance to $580–$600 million. Full-year profitability is now expected in 2025, with strong demand, international expansion, and pipeline progress supporting long-term growth.
-
ORLADEYO continues robust growth, with raised 2025 guidance and high retention rates, while ex-U.S. expansion and a strong pipeline—including pediatric and Netherton syndrome programs—support long-term prospects. Financials remain solid, with profitability and cash flow expected to strengthen.
-
Strong financial performance and expanding profitability are driven by ORLADEYO's commercial success and robust real-world data. Two pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, are advancing to clinical trials with initial patient data expected this year. Confidence remains high in achieving ambitious sales targets despite emerging competition.
-
Raised 2025 Orladeyo revenue guidance to $535–550M, driven by strong patient demand, improved paid drug rates, and robust real-world data. Pediatric NDA submission planned this year, and pipeline assets for Netherton syndrome and DME are advancing.
-
Revenue grew 34% in 2024, with strong U.S. and ex-U.S. demand and a path to $1B by 2029. Three major R&D milestones are expected in 2025, while robust financials and market research support durable growth and competitive positioning.
Fiscal Year 2024
-
Record 2024 performance with 34% ORLADEYO revenue growth, strong pipeline progress, and a $62.9M non-GAAP operating profit. 2025 guidance raised on robust demand and Medicare improvements, with positive cash flow and $1B global revenue targeted by 2029.
-
ORLADEYO continues strong growth as the only oral HAE prophylactic, with robust data supporting efficacy, high adherence, and expanding prescriber base. Pipeline advances include a pediatric oral formulation, a KLK5 inhibitor for Netherton syndrome, and Avoralstat for DME, with key data expected in 2025.
-
ORLADEYO continues to deliver strong growth, targeting $1 billion in revenue by 2029, with robust patient retention and a sticky market dynamic. Pipeline programs for Netherton syndrome and diabetic macular edema are advancing, while financials are improving with rising paid drug rates and a path to profitability.
-
Strong demand and improved paid therapy rates have driven revenue guidance higher, with profitability expected soon. Orladeyo’s market leadership is reinforced by high retention and payer progress, while pipeline assets for Netherton syndrome and DME are advancing with key data expected in 2025.
-
ORLADEYO revenue grew 36% year-over-year, driving strong operating profit and cash flow, with 2024 guidance raised to $430–$435 million. Pipeline advances include BCX17725 for Netherton syndrome and avoralstat for DME, both entering patient studies in 2025.
-
Orladeyo is driving strong revenue growth and market expansion, with robust real-world efficacy and increasing prescriber confidence. The company is advancing a diverse pipeline, targeting rare diseases and pediatric HAE, while maintaining a clear path to profitability and global growth.
-
ORLADEYO continues to drive strong patient and revenue growth, with robust U.S. and international expansion and a clear path to $1 billion in peak sales. Pipeline progress includes two new clinical programs, and financials show operating profitability with declining royalty obligations.
-
ORLADEYO continues robust growth, driven by patient preference for oral therapy and strong efficacy, with global sales expected to reach $1 billion by 2029. Pediatric expansion, new pipeline programs for rare diseases, and international launches support long-term growth.
-
ORLADEYO achieved record Q2 revenue, driving a 34% year-over-year increase and prompting a $30–$35 million upward revision in 2024 guidance. Operational improvements boosted paid patient rates and compliance, while pipeline progress and market expansion support a clear path to $1 billion peak revenue.
-
ORLADEYO's strong Q1 2024 growth is driven by robust patient demand and increasing paid patient rates, with 2024 sales expected to reach $390–$400 million. Profitability is on track for 2024–2026, while pipeline programs in PNH, Netherton syndrome, and DME advance toward key milestones.